

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Medical Research Council	10/12/2000
RECEIVING PARTY DATA	
Name:	Cambridge Drug Discovery Holdings LTD
Street Address:	10 Cambridge Science Park, Milton Road
City:	Cambridge CB4 OFG
State/Country:	UNITED KINGDOM
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	10732438
CORRESPONDENCE DATA	
Fax Number:	(877)769-7945
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	612-335-5070
Email:	knutson@fr.com
Correspondent Name:	J. Patrick Finn III, Ph.D.
Address Line 1:	60 South Sixth Street
Address Line 2:	3300 Dain Rauscher Plaza
Address Line 4:	Minneapolis, MINNESOTA 55402
ATTORNEY DOCKET NUMBER:	07039-415003
NAME OF SUBMITTER:	J. Patrick Finn III, Ph.D.
Total Attachments: 3 source=07039415001assignmentMedResearchtoCambridgeDrug#page1.tif source=07039415001assignmentMedResearchtoCambridgeDrug#page2.tif source=07039415001assignmentMedResearchtoCambridgeDrug#page3.tif	

CH \$40.00 10732438

ASSIGNMENT

In consideration of One Dollar (\$1.00) and other good and valuable considerations in hand paid, the receipt and sufficiency whereof are hereby acknowledged, the undersigned hereby assigns to: Cambridge Drug Discovery Holdings LTD, , a company incorporated in England, having a principal place of business at 10 Cambridge Science Park, Milton Road, Cambridge CB4 OFG, United Kingdom, its successors and assigns, the entire right, title and interest in the invention or improvements of the undersigned disclosed in an application for Letters Patent of the United States entitled:

<u>Inventors</u>	<u>Patent/Application No.</u>	<u>Filed/Issued</u>
------------------	-------------------------------	---------------------

Russell, <i>et al</i>	5,723,287	March 3, 1998
Title: Recombinant Viruses Displaying a Non Viral Peptide on Their External Surfaces		
Dates of Execution: September 13, 1995; September 15, 1995		

new Russell, <i>et al</i>	5,585,743 5,853,143	January 12, 1999
Title: Delivery of Nucleic Acids		
Dates of Execution: April 21, 1997; April 25, 1997; April 27, 1997		

Russell, <i>et al</i>	08/907,392	August 7, 1997
Title: Improvements in or Relating to Binding Assays		
Date of Execution: August 26, 1997		

Russell, <i>et al</i>	08/914,828	August 19, 1997
Title: Improvements in or Relating to Delivery of Nucleic Acids		
Dates of Execution: September 5, 1997; October 13, 1997; October 15, 1997; October 29, 1997		

Russell, <i>et al</i>	09/000,103	June 29, 1998
Title: Improvements in or Relating to Delivery of Nucleic Acids		
Dates of Execution: September 7, 1998; September 16, 1999		

Russell, <i>et al</i>	09/043,665	October 5, 1998
Title: Materials and Methods Relating to the Transfer of Nucleic Acid into Quiescent Cells		
Dates of Execution: June 10, 1998; June 15, 1998		

Russell, <i>et al</i>	09/020,147	February 6, 1998
Title: Improvements in or Relating to Methods of Screening Substances		
Dates of Execution: March 5, 1998; March 12, 1998		

Russell, et al 09/032,084 February 27, 1998
Title: **Recombinant Viruses Displaying a Non-Viral Peptide on Their External Surface**
Dates of Execution: July 2, 1998; July 4, 1998; July 16, 1998

Russell, et al 09/051,393 April 10, 1998
Title: **Improvements in or Relating to Protection Against Intracellular Infection**
Date of Execution: September 9, 1998

Russell, et al 09/070,630 April 30, 1998
Title: **Compositions and Methods for Elimination of Unwanted Cells**
Dates of Execution: February 7, 1998; May 18, 1998; June 2, 1998; July 2, 1998

Russell, et al 60/045,164 April 30, 1997
Title: **Compositions and Methods for Elimination of Unwanted Cells**
Date of Execution: October 3, 1997

Russell, et al 09/393,960 April 30, 1998
Title: **Compositions and Methods for Elimination of Unwanted Cells**
Dates of Execution: May 11, 1999; November 2, 1999; November 3, 1999,
November 8, 1999

Russell, et al 09/196,505 November 20, 1998
Title: **Improvements in or Relating to Regulation of T Cell Activation**
Dates of Execution: April 19, 1999; May 5, 1999; May 11, 1999; June 1, 1999

Russell, et al 60/076,448 March 2, 1998
Title: **Improvements in or Relating to Expression of Immunogenic Substances**
Dates of Execution: February 1, 1999; March 9, 1999

Russell, et al 60/083,657 April 30, 1998
Title: **Improvements in or Relating to Expression of Immunogenic Substances**
Dates of Execution: February 1, 1999; March 9, 1999

Russell, et al 09/197,056 November 20, 1998
Title: **Improvements in or Relating to Expression of Immunogenic Substances**
Dates of Execution: April 19, 1999; May 5, 1999; May 11, 1999; June 1, 1999

and in said application and any and all other applications, both United States and foreign, which the undersigned may file, either solely or jointly with others, on said invention or improvements, and in any and all Letters Patent of the United States and foreign countries, which may be obtained on any of said applications, and in any reissue or extension of such patents, and further assigns to said assignee the priority right provided by the International Convention.

The undersigned hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent to said assignee.

The undersigned warrant themselves to be the owners of the entire right, title and interest in said invention or improvements and to have the right to make this assignment, and further warrant that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.

For said consideration the undersigned hereby agree, upon the request and at the expense of said assignee, its successors and assigns, to execute any and all divisional, continuation and substitute applications for said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue or extension of any Letters Patent that may be granted upon said application and any and all applications and other documents for Letters Patent in foreign countries on said invention or improvements, that said assignee, its successors or assigns may deem necessary or expedient, and for the said considerations the undersigned authorize said assignee to apply for patents for said invention or improvements in its own name in such countries where such procedure is proper and further agree, upon the request of said assignees, its successors and assigns, to cooperate to the best of the ability of the undersigned with said assignee, its successors and assigns, in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain, maintain and enforce said Letters Patent, both United States and foreign, and vest all rights therein hereby conveyed in the assignees, its successors and assigns, whereby said Letters Patent will be held and enjoyed by the said assignees, its successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the undersigned if this assignment had not been made.

M. R. Wood
Martin Richard Wood
for Medical Research Council

12.06.94 2000
Date

Martin R Wood PhD
Director, Licensing and Agreements
Medical Research Council Technology